Search results for "Viral hepatitis"

showing 10 items of 132 documents

Prevalence of Autoantibodies to the p53 Protein in Autoimmune Hepatitis

2003

The target antigens of anti-nuclear autoantibodies in autoimmune hepatitis (AIH) are poorly characterised. Since antibodies to the p53 nuclear protein have been reported in various autoimmune diseases, we have assessed the prevalence of these antibodies in patients with AIH (n = 45), primary biliary cirrhosis (n = 60), hepatitis B (n = 22), hepatitis C (n = 55), and in a control group of subjects with various non-liver diseases (n = 56). A significant proportion of patients with AIH (31%) had elevated levels of autoantibodies to the p53 protein. In contrast, the prevalence of these antibodies in primary biliary cirrhosis (8%) and viral hepatitis (6%) was similar to that in the control group…

MaleHepatitisAutoimmune diseasebusiness.industryImmunologyAutoantibodyAutoimmune hepatitisHepatitis CMiddle AgedHepatitis Bmedicine.diseasedigestive system diseasesHepatitis AutoimmunePrimary biliary cirrhosisimmune system diseasesImmunologymedicineHumansImmunology and AllergyFemaleTumor Suppressor Protein p53businessViral hepatitisAutoantibodiesAutoimmunity
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

Recent insights into the relationship between inflammatory liver diseases and atherosclerosis.

2011

Atherosclerosis is a dynamic process in the human body. Many studies have evaluated atherosclerosis and its relationship with other systems in the body. Our perception of its pathogenesis is evolving with the introduction of new players in the game. It is no longer possible to consider the atherosclerosis as an independent process, unaffected by the liver and its function. Although several tasks performed by the liver, such as lipid metabolism, have been implicated in the pathogenesis of atherosclerosis, the role of other disorders of the liver (autoimmune diseases, viral hepatitis, and cirrhosis) are not fully understood. In this review, the most commonly encountered inflammatory liver di…

MaleRiskHepatitis B virusCirrhosisInflammationHepacivirusBiologyGeneral Biochemistry Genetics and Molecular BiologyAutoimmune DiseasesHepatitisPathogenesisFibrosisPrevalencemedicineHumansInflammationHepatitisCholestasisLiver DiseasesResearchFatty liverLipid metabolismGeneral MedicineAtherosclerosismedicine.diseasehepatitis B hepatitis C hepatitis A inflammation fatty liver atherosclerosisFibrosisFatty LiverLiverImmunologyFemalemedicine.symptomViral hepatitis
researchProduct

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

2019

Background and Aims: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction. Methods: A total of 103 TDF-treated patients were included as follows: age 64 years, 83% male, 49% cirrhotics, 98% with undetectable HBV DNA, 47% with previous lamivudine resistance (LMV-R) and 71% previously treated with adefovir. Twenty-nine (28%) were switched to ETV because estimated glomerular filtration rate (e…

MaleTime FactorsSustained Virologic Responsehepatitis B viruKidneyGastroenterologyhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitischemistry.chemical_compound0302 clinical medicine80 and overAdefovirChronicAged 80 and overKidneymedicine.diagnostic_testDrug Substitutionhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; HepatologyEntecavirMiddle AgedHepatitis BHepatitis BTreatment Outcomemedicine.anatomical_structureItaly030220 oncology & carcinogenesisFemaleKidney Diseases030211 gastroenterology & hepatologyViral hepatitismedicine.drugAdultmedicine.medical_specialtyGuaninehepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; Adult; Aged; Aged 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B Chronic; Humans; Italy; Kidney; Kidney Diseases; Male; Middle Aged; Recovery of Function; Retrospective Studies; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome; Drug Substitutionviral hepatitisRenal functionliverAntiviral Agents03 medical and health sciencesHepatitis B ChronicInternal medicinerenal dysfunctionmedicineHumansliver function testTenofovirAgedRetrospective StudiesCreatinineHepatologybusiness.industryviral hepatitiRecovery of Functionmedicine.diseasechemistryliver function testsbusinessLiver function testshepatitis B virus
researchProduct

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

2010

Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the standard of care for adults with chronic hepatitis C but was not approved for the treatment of children at the time of this study. The aim of this study was to evaluate the efficacy and safety of PEG-IFN alfa-2b plus RBV in children.Children and adolescents ages 3-17 years were treated with PEG-IFN alfa-2b (60microg/m(2)/week) plus RBV (15mg/kg/day). The duration of therapy was 24 weeks for genotype (G) 2 and G3 patients with low viral load (600,000IU/ml) and 48 weeks for G1, G4, and G3 with high viral load (or=600,000IU/ml). The primary end point was sustained virologic response (SVR), defined as undetectable hepatitis C vi…

Malemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundChild DevelopmentPegylated interferonInternal medicineDrug Resistance ViralRibavirinmedicineHumansChildAdverse effectHepatologybusiness.industryRibavirinBody WeightInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseBody HeightRecombinant ProteinsTreatment OutcomechemistryChild PreschoolImmunologyPeginterferon alfa-2bDrug Therapy CombinationFemaleViral hepatitisbusinessViral loadmedicine.drugJournal of Hepatology
researchProduct

Hepatocellular carcinoma in patients with autoimmune hepatitis.

2009

To evaluate and confirm the low incidence of hepatocellular carcinoma (HCC) in patients with autoimmune hepatitis (AIH). At present only very few cases of HCC in patients with AIH and definite exclusion of chronic viral hepatitis have been published, suggesting that HCC due to AIH is rare.In order to further investigate the incidence of HCC in patients with AIH, we reviewed our large cohort of 278 patients with AIH.Eighty-nine patients (32%) were diagnosed with liver cirrhosis, a preneoplastic condition for HCC. We studied a total of 431 patient years of cirrhosis in these patients, an average 4.8 years per patient. During this period none of the patients of our own study cohort developed H…

Malemedicine.medical_specialtyCirrhosisAsiaCarcinoma HepatocellularAutoimmune hepatitisGastroenterologyCohort StudiesHepatitis B Chronicimmune system diseasesInternal medicineMedicineHumansneoplasmsAfrica South of the SaharaAgedHepatitisbusiness.industryLiver Cirrhosis BiliaryDeveloped CountriesIncidenceLiver NeoplasmsGastroenterologyGeneral MedicineHepatitis CHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseasesBrief ArticlesHepatitis AutoimmuneHepatocellular carcinomaFemaleHemochromatosisbusinessLiver cancerViral hepatitisWorld journal of gastroenterology
researchProduct

Significance of the effective remnant liver volume in major hepatectomies

2005

The aim of this study is to identify the minimum safe amount of effective remnant liver volume (ERLV) in patients undergoing a major hepatectomy. Thirty-eight consecutive major hepatectomies (resection of ≥3 Couinaud segments) performed between July 1999 and March 2004 in which a frozen section liver biopsy was obtained were included. No patient had chronic viral hepatitis, cirrhosis, or cholestasis. The total liver volume (TLV) was calculated using the Vauthey formula, and the postsurgical liver volume (PSLV) was derived by subtracting the estimated volume of liver resected from the TLV. The PSLV minus the percentage of macrovesicular steatosis as nonfunctional liver was defined as the ef…

Malemedicine.medical_specialtyCirrhosisRisk AssessmentCohort StudiesPostoperative ComplicationsCholestasisLiver Function TestsmedicineHepatectomyHumansSurvival analysisProbabilityRetrospective StudiesCohort Studies; Female; Follow-Up Studies; Hepatectomy; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Organ Size; Postoperative Complications; Probability; Retrospective Studies; Risk Assessment; Survival AnalysisFrozen section proceduremedicine.diagnostic_testbusiness.industryLiver NeoplasmsRetrospective cohort studyGeneral MedicineOrgan Sizemedicine.diseaseSurvival AnalysisSurgerySettore MED/18 - Chirurgia GeneraleLiverLiver biopsyFemaleLiver function testsbusinessViral hepatitisFollow-Up Studies
researchProduct

Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy.

2012

The level of endemicity of hepatitis B virus (HBV) infections in Italy is low and genotype D infections predominant. New HBV strains may however be introduced as a result of movements of people from regions of high endemicity. The aim of the present study was to determine whether strains from new cases of acute hepatitis B detected in southern Italy were due to endemic or new HBV strains. We studied 34 isolates from patients with acute hepatitis B infection, and 35 from chronic hepatitis B patients. A phylogenetic analysis of preS/S region was done by comparing the sequences from the acute and chronic cases with references sequences. The study showed that 44% of strain from acute hepatitis …

Microbiology (medical)AdultMalemedicine.medical_specialtyHepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeBiologymedicine.disease_causeMicrobiologyLiver diseaseEpidemiologyGenotypeGeneticsmedicineHumansMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedHepatitis B virusAged 80 and overMolecular EpidemiologySettore MED/12 - GastroenterologiaMolecular epidemiologyPhylogenetic treeSequence Analysis DNAHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyInfectious DiseasesItalyImmunologyDNA ViralFemaleViral hepatitisHBV genotypes molecular epidemiology Acute HBV infection phylogenetic analysis
researchProduct

Antibodies to hepatitis B virus x-protein in sera of patients with acute and chronic acitve hepatitis

1989

Sera of patients with acute (AH) and chronic active hepatitis (CAH) were tested for anti-hepatitis B virus (HBV) x-protein (HBx) by immunoblotting, using recombinant MS2- and beta gal-HBx fusion proteins as substrate. Antibodies against HBx were detected in 5 out of 17 patients with AH at an early stage of infection, and in 13 out of 35 patients with CAH. Positive sera from AH patients showed a relatively weak anti-HBx reactivity when compared to sera from CAH patients. In follow up studies we tested serial serum samples from patients positive for anti-HBx. Patients with AH were observed for 3 to 6 weeks and CAH patients for up to 51 months. In general anti-HBx reactivities appeared to be s…

Microbiology (medical)Hepatitis B virusmedicine.medical_specialtyRecombinant Fusion ProteinsvirusesBlotting WesternImmunologyViruslaw.inventionViral ProteinsMedical microbiologylawmedicineHumansImmunology and AllergyHepatitis B AntibodiesTransaminasesHepatitis ChronicHepatitisbiologybusiness.industryGeneral MedicineHepatitis Bmedicine.diseasedigestive system diseasesHBxImmunologybiology.proteinRecombinant DNAViral diseaseAntibodyViral hepatitisbusinessMedical Microbiology and Immunology
researchProduct

The role of positive selection in hepatitis C virus

2008

Hepatitis C virus (HCV) is a major health problem worldwide, infecting an estimated 170 million people. In this study, we have employed a large data set of sequences (14,654 sequences from between 25 and 100 clone sequences per analyzed region and per patient) from 67 patients infected with HCV genotype 1 (23 subtype 1a and 44 subtype 1b). For all patients, a sample prior to combined therapy with alpha interferon plus ribavirin was available, whereas for some patients additional samples after 6 or 12 months of treatment were also available. Twenty-seven patients responded to treatment (12 subtype 1a and 15 subtype 1b) and forty patients did not respond to treatment (11 subtype 1a vs. 29 sub…

Microbiology (medical)Hepatitis C virusAlpha interferonHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeMicrobiologyCohort Studieschemistry.chemical_compoundViral Envelope ProteinsSequence Analysis ProteinInterferonDrug Resistance ViralRibavirinGeneticsmedicineHumansAmino Acid SequenceSelection GeneticNS5AMolecular BiologyEcology Evolution Behavior and SystematicsChi-Square DistributionRibavirinInterferon-alphaHepatitis Cmedicine.diseaseComplementarity Determining RegionsHepatitis CVirologyHypervariable regionInfectious DiseaseschemistryImmunologyViral hepatitismedicine.drugInfection, Genetics and Evolution
researchProduct